Longdom Conferences

Scientific program

Sep 26-27, 2022    Dubai, UAE
2nd International Conference on

Nephrology

  • Home -
  • Scientific program

Keynote Forum

Baris Cankaya
1

Baris Cankaya

Marmara University Pendik Training Hospital, Turkey

Title: Kidney Disease

Abstract:

Perioperative fluid therapy management is a very difficult process. Perioperative morbidity is associated with the amount of intravenous fluid delivered and consequent postoperative complications. Not only fluid, its component and hemodynamic parameters also play important role. Studies have shown that combining fluid therapy with the goal of hemodynamic stabilization can minimize postoperative complications. Perioperative hypovolemia leads to organ dysfunction, since adaptive mechanisms cause peripheral vasoconstriction to maintain blood flow to the vital organs. Anesthetized patients often present with a functional intravascular volume deficit depending on many factors. Fluid management is a key topic for achieving advanced recovery after surgery. It is important to plan a tailor-cut fluid resuscitation for the patient perioperatively avoiding postoperative complications.

Biography:

Baris Canaya is an Anesthesiologist at Marmara University Pendik Training Hospital in Istanbul, Turkey. He has deep interest for resuscitation, acute critical illness, trauma anesthesia, pediatric congenital cardiovascular anesthesia and perioperative patient safety. 

Speakers

Kidney Transplantation and Robotic Surgery
2

Kidney Transplantation and Robotic Surgery

Tokyo

Title: Kidney Transplantation and Robotic Surgery

Workshop

Paediatric Nephrology
1

Paediatric Nephrology

Tokyo

Title: Paediatric Nephrology

Video Presentation

Hany Helmy Saad Attia
2

Hany Helmy Saad Attia

Shobra General Hospital Egypt

Title: Diabetic Nephropathy

Abstract:

Aim: Permcath. Is a known vascular acess for haemodialysis patients, which may last for 2 years or more.it is a 1st line for hemodialysis for patients who were not prepaired by AVF few months before starting dialysis ,but in Egypt most of patients start dialysis with temporarily catheters (cheap)but causes stricture or occlusion of the used central vein. Method: We studied 146 patients who were submitted for permcath. Insertion in our hospital as regard:the vein used-cause of insertion –failure of insertion or using it in dialysis and longevity. Result: The results were as following: *64 (rt, int. jugular) 1- 16 were 1st prick 2-26 were waiting for maturity of AVF 3-20 due to cardiac causes 4-02 due to failed multiple AVF *30(rt. Subclavian) 1-09 were waiting for maturity of AVF 2-11 due to cardiac cuses 3-10 due to failed multiple AVF *15(left jugular) all has thromosed rt. Int. jugular 1- 06 were waiting for maturity of delayed AVF 2- 09 due to failure of multiple AVF *07(left subclavian) all were due failure of multiple AVF *30(femoral vein ) all of them has no available vascular access and 12 of them had cardiac causes Conclusion: From this study we found that most patients who were referred for permcath .insertion had a history of single or multiple temporarily catheter insertion that caused single or multiple central vein occlusion Suggestion: we recommend to use permcath. As a first prick in patients who are not prepared by AVF and avoid using temporarily catheters to save veins of patients, because the use of temporarily catheters causes stricture or occlusion of central veins

Biography:

Hany Helmy Saad Attia has completed his Master degree in Internal Medicine and a Master Degree in Nephrology From Ain Shams University in Egypt. He is currently working as the Head of Nephrology at the department of Shobra General Hospital

Useful Links

News

Why Racial and Ethnic Disparities Exist in Kidney Disease Care

2021-04-05 - 2021-04

Racial and ethnic disparities permeate much of the healthcare system in the United States. Numerous studies have documented that Black individuals ...

Kerendia Approved to Reduce CKD Progression, CV Risk in Patients With Diabetic Kidney Disease

2021-07-14 - 2021-07

The Food and Drug Administration (FDA) has approved Kerendia® (finerenone) to reduce the risk of sustained estimated glomerular filtration (eGFR) decline, end stage kidney disease, cardiovascular death, nonfatal myocardial infarction (MI) and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D). Kerendia is a nonsteroidal selective mineralocorticoid receptor (MR) antagonist that works by blocking MR mediated sodium reabsorption and MR overactivation in both epithelial (eg, kidney) and nonepithelial (eg, heart and blood vessels) tissues. Mineralocorticoid receptor overactivation is believed to contribute to fibrosis and inflammation.

CKD Hospitalization Patterns May Predict ESKD, Death Risks

2021-07-06 - 2021-07

Patients with chronic kidney disease (CKD) who are more frequently hospitalized are more likely progress to end-stage kidney disease (ESKD) or die compared with patients who are rarely hospitalized, independent of traditional risk factors, a new study finds. Among 3012 individuals with CKD stages 2 to 4 in the Chronic Renal Insufficiency Cohort (CRIC) study, 5658 hospitalizations occurred within 4 years. The high-, intermediate-, and low-utilizer groups had a mean 6.3, 2.2, and 0 all-cause hospitalizations, respectively, over the period, Anand Srivastava, MD, MPH, of Northwestern University Feinberg School of Medicine in Chicago, Illinois, and colleagues reported in Kidney International Reports. For both high and intermediate utilizers, the top 5 reasons for hospitalization were circulatory system disorders, infectious diseases, endocrine disorders, musculoskeletal system disorders, and injury and poisoning. High utilizers had a significantly longer hospital stay compared with intermediate and low utilizers: 1.6 vs 0.5 vs 0 days, respectively, according to the investigators. Patients in the high-utilizer group also were significantly more likely to be rehospitalized within 30 days: 31.4% vs 12.9% vs 0%, respectively. After the 4 year period, 544 ESKD events and 437 ESKD-censored deaths occurred during a median follow-up duration of 5.1 years. In adjusted analyses, intermediate and high utilizers had a 1.5- and 1.8-fold higher risk of ESKD, respectively, compared with low utilizers, Dr Srivastava’s team reported. Intermediate and high utilizers also had a 1.5- and 2.6-fold higher risk of ESKD-censored death, respectively.

CKD Hospitalization Patterns May Predict ESKD, Death Risks

2021-07-06 - 2021-07

Patients with chronic kidney disease (CKD) who are more frequently hospitalized are more likely progress to end-stage kidney disease (ESKD) or die compared with patients who are rarely hospitalized, independent of traditional risk factors, a new study finds. Among 3012 individuals with CKD stages 2 to 4 in the Chronic Renal Insufficiency Cohort (CRIC) study, 5658 hospitalizations occurred within 4 years. The high-, intermediate-, and low-utilizer groups had a mean 6.3, 2.2, and 0 all-cause hospitalizations, respectively, over the period, Anand Srivastava, MD, MPH, of Northwestern University Feinberg School of Medicine in Chicago, Illinois, and colleagues reported in Kidney International Reports. For both high and intermediate utilizers, the top 5 reasons for hospitalization were circulatory system disorders, infectious diseases, endocrine disorders, musculoskeletal system disorders, and injury and poisoning. High utilizers had a significantly longer hospital stay compared with intermediate and low utilizers: 1.6 vs 0.5 vs 0 days, respectively, according to the investigators. Patients in the high-utilizer group also were significantly more likely to be rehospitalized within 30 days: 31.4% vs 12.9% vs 0%, respectively. After the 4 year period, 544 ESKD events and 437 ESKD-censored deaths occurred during a median follow-up duration of 5.1 years. In adjusted analyses, intermediate and high utilizers had a 1.5- and 1.8-fold higher risk of ESKD, respectively, compared with low utilizers, Dr Srivastava’s team reported. Intermediate and high utilizers also had a 1.5- and 2.6-fold higher risk of ESKD-censored death, respectively.

Newsletter

© 2024 All Rights Reserved by Longdom